Javascript must be enabled to continue!
Relationship between serum NDRG3 and papillary thyroid carcinoma
View through CrossRef
BackgroundIn recent years, papillary thyroid carcinoma is considered to be one of the fastest increaseing cancer. NDRG family member 3 (NDRG3) has been proposed as a molecular marker of tumor, and is expected to be used in clinic.MethodsEnzyme-linked immunosorbent assay was used to detect the serum NDRG3 expression in 81 papillary thyroid carcinoma cases, 75 benign thyroid nodules cases and 77 healthy control cases, respectively. Electrochemiluminescence method was applied to measure the levels of triiodothyronine, tetraiodothyronine, thyrotropin, thyroglobulin antibody and thyroid peroxidase antibody. Immunohistochemical staining was used to detect the expression of NDRG3 in papillary thyroid carcinoma, benign thyroid nodules and normal tissues adjacent to cancer.ResultsThe expression of serum triiodothyronine, tetraiodothyronine, thyrotropin, thyroglobulin antibody and thyroid peroxidase antibody and NDRG3 were significantly different among benign thyroid nodules, papillary thyroid carcinoma cases and healthy control groups (P <0.001). Only the expression of serum NDRG3 was significantly different between benign thyroid nodules and papillary thyroid carcinoma groups (P <0.001). Immunohistochemistry showed that NDRG3 was expressed in all three groups, the lowest in papillary thyroid carcinoma, the second in benign thyroid nodules, and the highest in normal tissues adjacent to cancer. Logistic regression analysis showed that serum NDRG3 was an independent protective factor for papillary thyroid carcinoma (OR =0.964, 95%CI =0.953 to 0.974, P <0.001). The ROC curve of non-papillary thyroid carcinoma diagnosed by serum NDRG3 showed the optimal cut-off value of 481.38 pg/ml, sensitivity of 72.4%, specificity of 90.1%, and the maximum area under the curve (AUC =0.902, 95%CI =0.863 to 0.940, P <0.001). The ROC curve of benign thyroid nodules diagnosed by serum NDRG3 showed the optimal critical value of 459.28 pg/ml, sensitivity of 81.3%, and specificity of 74.1% (AUC =0.863, 95%CI =0.808 to 0.919, P <0.001). The expression level of serum NDRG3 was significantly correlated with extrathyroid extensionand (P =0.007) and lymphatic metastasis of papillary thyroid carcinoma (P =0.019).ConclusionsThe decrease of NDRG3 expression can not only differential diagnosis benign thyroid nodules and papillary thyroid carcinoma, but also serve as a molecular marker for the diagnosis of papillary thyroid carcinoma.
Frontiers Media SA
Title: Relationship between serum NDRG3 and papillary thyroid carcinoma
Description:
BackgroundIn recent years, papillary thyroid carcinoma is considered to be one of the fastest increaseing cancer.
NDRG family member 3 (NDRG3) has been proposed as a molecular marker of tumor, and is expected to be used in clinic.
MethodsEnzyme-linked immunosorbent assay was used to detect the serum NDRG3 expression in 81 papillary thyroid carcinoma cases, 75 benign thyroid nodules cases and 77 healthy control cases, respectively.
Electrochemiluminescence method was applied to measure the levels of triiodothyronine, tetraiodothyronine, thyrotropin, thyroglobulin antibody and thyroid peroxidase antibody.
Immunohistochemical staining was used to detect the expression of NDRG3 in papillary thyroid carcinoma, benign thyroid nodules and normal tissues adjacent to cancer.
ResultsThe expression of serum triiodothyronine, tetraiodothyronine, thyrotropin, thyroglobulin antibody and thyroid peroxidase antibody and NDRG3 were significantly different among benign thyroid nodules, papillary thyroid carcinoma cases and healthy control groups (P <0.
001).
Only the expression of serum NDRG3 was significantly different between benign thyroid nodules and papillary thyroid carcinoma groups (P <0.
001).
Immunohistochemistry showed that NDRG3 was expressed in all three groups, the lowest in papillary thyroid carcinoma, the second in benign thyroid nodules, and the highest in normal tissues adjacent to cancer.
Logistic regression analysis showed that serum NDRG3 was an independent protective factor for papillary thyroid carcinoma (OR =0.
964, 95%CI =0.
953 to 0.
974, P <0.
001).
The ROC curve of non-papillary thyroid carcinoma diagnosed by serum NDRG3 showed the optimal cut-off value of 481.
38 pg/ml, sensitivity of 72.
4%, specificity of 90.
1%, and the maximum area under the curve (AUC =0.
902, 95%CI =0.
863 to 0.
940, P <0.
001).
The ROC curve of benign thyroid nodules diagnosed by serum NDRG3 showed the optimal critical value of 459.
28 pg/ml, sensitivity of 81.
3%, and specificity of 74.
1% (AUC =0.
863, 95%CI =0.
808 to 0.
919, P <0.
001).
The expression level of serum NDRG3 was significantly correlated with extrathyroid extensionand (P =0.
007) and lymphatic metastasis of papillary thyroid carcinoma (P =0.
019).
ConclusionsThe decrease of NDRG3 expression can not only differential diagnosis benign thyroid nodules and papillary thyroid carcinoma, but also serve as a molecular marker for the diagnosis of papillary thyroid carcinoma.
Related Results
Primary Thyroid Non-Hodgkin B-Cell Lymphoma: A Case Series
Primary Thyroid Non-Hodgkin B-Cell Lymphoma: A Case Series
Abstract
Introduction
Non-Hodgkin lymphoma (NHL) of the thyroid, a rare malignancy linked to autoimmune disorders, is poorly understood in terms of its pathogenesis and treatment o...
Clinicopathological Features of Indeterminate Thyroid Nodules: A Single-center Cross-sectional Study
Clinicopathological Features of Indeterminate Thyroid Nodules: A Single-center Cross-sectional Study
Abstract
Introduction
Due to indeterminate cytology, Bethesda III is the most controversial category within the Bethesda System for Reporting Thyroid Cytopathology. This study exam...
Breast Carcinoma within Fibroadenoma: A Systematic Review
Breast Carcinoma within Fibroadenoma: A Systematic Review
Abstract
Introduction
Fibroadenoma is the most common benign breast lesion; however, it carries a potential risk of malignant transformation. This systematic review provides an ove...
Kikuchi-Fujimoto Disease Coexistent with Papillary Thyroid Carcinoma: A Report of Two Cases
Kikuchi-Fujimoto Disease Coexistent with Papillary Thyroid Carcinoma: A Report of Two Cases
Abstract
Introduction
Kikuchi-Fujimoto Disease (KFD), characterized by histiocytic necrotizing lymphadenitis, is a rare condition of unknown etiology. Diagnosis is dependent on lym...
SAT567 Collision Tumor Of The Thyroid With Papillary Thyroid Carcinoma And Metastatic Renal Clear Cell Carcinoma With Concomitant Parathyroid Adenoma
SAT567 Collision Tumor Of The Thyroid With Papillary Thyroid Carcinoma And Metastatic Renal Clear Cell Carcinoma With Concomitant Parathyroid Adenoma
Abstract
Disclosure: C.M. Mirano: None. R.C. Mirasol: None.
INTRODUCTION Collision tumors of the thyroid are rare diseases that have two or more histo...
Coexistence of Papillary Thyroid Carcinoma in Secondary Hyperparathyroidism
Coexistence of Papillary Thyroid Carcinoma in Secondary Hyperparathyroidism
Abstract
Background: Coexistence of primary hyperparathyroidism and papillary thyroid carcinoma is common and may be associative with more aggressive papillary thyroid carc...
Molecular prognostication of thyroid tumors : with special focus on TERT
Molecular prognostication of thyroid tumors : with special focus on TERT
<p dir="ltr">Thyroid carcinoma is the most common endocrine malignancy, with its incidence steadily increasing worldwide. These tumors can be challenging to diagnose, and tre...
Molecular prognostication of thyroid tumors : with special focus on TERT
Molecular prognostication of thyroid tumors : with special focus on TERT
<p dir="ltr">Thyroid carcinoma is the most common endocrine malignancy, with its incidence steadily increasing worldwide. These tumors can be challenging to diagnose, and tre...


